JAK2 and myeloproliferative disorder: However, this positive result did not fulfil the complete diagnostic criteria for up to 80% of BCS patients and 50% of EHPVO patients.25 Recently, the JAK2 V617F mutation has been reported to be the main molecular marker of the Philadelphia-negative MPN.